AstraZeneca PLC vs CYATY
A head-to-head of AstraZeneca PLC (AZN) and CYATY (CYATY) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | AZN | CYATY |
|---|---|---|
| Market Cap | $289.41B | $372.43B |
| P/E (TTM) | 14.26 | 31.75 |
| Forward P/E | 18.12 | 29.07 |
| P/S | 4.93 | 0.80 |
| P/B | 3.00 | 6.98 |
| EV/EBITDA | 16.16 | 16.60 |
| Dividend Yield | 3.41% | 0.00% |
| Profit Margin | 17.41% | 16.87% |
| Gross Margin | 81.90% | 25.62% |
| Operating Margin | 23.40% | 15.29% |
| Revenue Growth (YoY) | +4.11% | +52.45% |
| FCF Yield | 3.65% | 23.93% |
| Debt / Equity | 58.11 | 27.90 |
| Current Ratio | 0.94 | 1.60 |
Which is better: AstraZeneca PLC or CYATY?
- ✓Larger by market cap: CYATY
- ✓Cheaper valuation (lower P/E): AstraZeneca PLC
- ✓Higher dividend yield: AstraZeneca PLC
- ✓More profitable (net margin): AstraZeneca PLC
- ✓Faster revenue growth: CYATY
- ✓Higher free-cash-flow yield: CYATY
Across 13 available metrics, AstraZeneca PLC leads 8–5.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
Compare AstraZeneca PLC with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.